Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has earned a consensus recommendation of “Hold” from the twenty-three analysts that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $20.4565.

A number of equities analysts recently weighed in on NTLA shares. Leerink Partners set a $35.00 price objective on shares of Intellia Therapeutics in a report on Monday, April 27th. Wedbush reiterated a “neutral” rating and set a $12.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 15th. The Goldman Sachs Group lifted their target price on Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a report on Tuesday, April 28th. Robert W. Baird boosted their price target on Intellia Therapeutics from $7.00 to $13.00 and gave the stock a “neutral” rating in a research note on Monday, April 27th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a report on Monday, June 15th.

Insider Activity at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 4,677 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the transaction, the executive vice president directly owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Michael P. Dube sold 2,641 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the transaction, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NTLA. Caitong International Asset Management Co. Ltd bought a new stake in Intellia Therapeutics during the 3rd quarter valued at approximately $30,000. Advisory Services Network LLC bought a new position in Intellia Therapeutics during the third quarter valued at $33,000. Headlands Technologies LLC purchased a new position in Intellia Therapeutics in the second quarter worth about $26,000. Comerica Bank boosted its holdings in Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares during the period. Finally, Danske Bank A S bought a new stake in Intellia Therapeutics during the 3rd quarter valued at about $50,000. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $16.84 on Thursday. Intellia Therapeutics has a one year low of $7.95 and a one year high of $28.25. The company’s 50-day moving average is $14.32 and its 200 day moving average is $13.25. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -4.76 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The business had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. During the same period in the previous year, the company earned ($1.10) earnings per share. As a group, research analysts predict that Intellia Therapeutics will post -3.18 earnings per share for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.